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Hsp90 is an essential chaperone responsible for trafficking a vast array of client proteins,
which are substrates that Hsp90 regulates in eukaryotic cells under stress conditions.
The ATP-binding N-terminal domain of Hsp90 (also known as a GHKL type ATPase
domain) can serve as a specific drug target, because sufficient structural diversity in
the ATP-binding pocket of Hsp90 allows for ortholog selectivity of Hsp90 inhibitors. The
primary objective of this study is to identify inhibitors specific for the ATP-binding domain
of Entamoeba histolytica Hsp90 (EhHsp90). An additional aim, using a combination of
site-directed mutagenesis and a protein in vitro assay, is to show that the antiparasitic
activity of Hsp90 inhibitors is dependent on specific residues within the ATP-binding
domain. Here, we tested the activity of 43 inhibitors of Hsp90 that we previously
identified using a high-throughput screen. Of the 43 compounds tested, 19 competed
for binding of the EhHsp90 ATP-binding domain. Five out of the 19 EhHsp90 protein
hits demonstrated activity against E. histolytica in vitro culture: rifabutin, rutilantin,
cetylpyridinium chloride, pararosaniline pamoate and gentian violet. These five top E.
histolytica Hsp90 inhibitors showed 30–100% inhibition of E. histolytica in culture in the
micromolar range. These data suggest that E. histolytica-specific Hsp90 inhibitors are
possible to identify and provide important lead compounds for the development of novel
antiamebic drugs.
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Introduction
Entamoeba histolytica is a protozoan intestinal parasite that causes amebiasis worldwide (Walsh,
1986), Amebiasis presents as diarrhea in humans causing 50 million cases of invasive disease and
70–100 thousand deaths worldwide (Stanley, 2003; Ralston and Petri, 2011b). Current therapy relies
solely on metronidazole and is complicated by resistance and adverse neurotoxic, mutagenic and
carcinogenic effects (Freeman et al., 1997; Kapoor et al., 1999; Bendesky et al., 2002). Considering
the prevalence of amebiasis and the lack of other therapeutic options, it is of paramount importance
to search for other effective, better-tolerated antiamebic drugs. To this end, we propose the
discovery of new antiamebic drugs by targeting heat shock protein 90 (Hsp90), one of the
best-studied members of the heat shock protein (HSP) family.
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Stress inducible cytosolic Hsp90 exists in the form of a multi-
chaperone complex and is essential for helping client proteins to
fold (Li and Buchner, 2013). As such, it is essential for normal
eukaryotic growth and development (Li and Buchner, 2013).
The existing model suggests that the stress inducible isoform
of cytosolic Hsp90 serves as a buffer of phenotypic variation
and potentiator of drug resistance by preventing cellular toxicity
caused by misfolded and aggregated proteins in response to
heat shock or pharmacological stress (Cowen and Lindquist,
2005; Cowen et al., 2009; Marubayashi et al., 2010). Many
Hsp90 clients are essential cellular proteins with pathogenic
functions that render the inhibition of the Hsp90 pathway lethal
in cells undergoing pathogenic, pharmacological or heat-shock
stress, but not in normal cells (Cowen and Lindquist, 2005;
Chiosis et al., 2006; Cerchietti et al., 2009, 2010; Cowen et al.,
2009; Taldone et al., 2010). Pharmacologic inhibition of Hsp90
effectively results in lethality in abnormal cells such as infected or
transformed cells by disruption of the broad spectrum of Hsp90
interactions and signaling pathways (Jhaveri et al., 2011; Usmani
and Chiosis, 2011). As such, this inhibition provides specific
anti-disease effects and a decreased likelihood for developing
resistance.
In particular, inhibition of this ATPase activity at the
N-terminal ATP-binding domain is an effective approach for
blocking its function and interaction with client proteins (Jhaveri
et al., 2011; Usmani and Chiosis, 2011). Significant similarity
exists at the ATP-binding domain between other eukaryotic
stress-inducible Hsp90s and parasite Hsp90s such as Plasmodium
falciparumHsp90 (PfHsp90) and E. histolyticaHsp90 (EhHsp90)
(Banumathy et al., 2003; Pavithra et al., 2004, 2007; Acharya et al.,
2007; Kumar et al., 2007; Pallavi et al., 2010). In addition, the
pocket architecture of the orthologous ATP binding domains of
stress inducible Hsp90 also contains unique residues that can be
selectively targeted by inhibitors (Wider et al., 2009; Corbett and
Berger, 2010; Pallavi et al., 2010). Such unique residues may be
involved in ligand binding, but do not participate in the catalytic
function of this domain, because residues involved in catalysis
are essential for the ATPase function of this domain and are
therefore conserved (Wider et al., 2009; Corbett and Berger, 2010;
Pallavi et al., 2010). For example, crystal structures of human and
P. falciparum Hsp90 N-terminal domains (PDB ID: 2FWZ and
3K60, respectively) reveal that PfHsp90 Met84 adopts a different
side-chain rotamer than human Met98, altering the shape of
the “ceiling” of the binding pocket (Corbett and Berger, 2010).
Ser52, Lys112 and Val186 of human (Hs) Hsp90 are replaced by
Ala38, Arg98 and Ile173 in PfHsp90 (Corbett and Berger, 2010).
Even though these residues are not involved in ATP hydrolysis
(Corbett and Berger, 2010), in general, these differences in pocket
architecture suggest that the PfHsp90 ATP-binding domain is
slightly more hydrophobic, constricted, and basic relative to the
human ortholog (Corbett and Berger, 2010).
We hypothesize that targeting of cytosolic-inducible Hsp90 is
a viable strategy for drug discovery as this protein is essential
in most eukaryotes studied to date e.g., Drosophila melanogaster
(Bandura et al., 2013), Caenorhabditis elegans (Inoue et al., 2003),
P. falciparum (Banumathy et al., 2003). In addition, conservation
of theN-terminus ATP binding domain suggests that this domain
is under selection pressure to be conserved so that it may provide
the energy needed to fold client proteins. Due to both this
conservation, and presence of unique residues that may confer
selectivity, repurposing of previously identified Hsp90 inhibitors
is an attractive strategy and opportunity to capitalize on existing
safety and pharmacokinetic data. Therefore, we tested the effect
of 43 previously identified HsHsp90 and P. falciparum (PfHsp90)
(Shahinas et al., 2010) inhibitors for their ability to inhibit
EhHsp90. The objectives of this study were: (1) to biochemically
characterize and identify the unique residues in the ATP binding
pocket of HsHsp90 vs. EhHsp90; (2) to explore the selectivity of
binding of these inhibitors to EhHsp90, PfHsp90 and HsHsp90 as
well as to the site-directed mutants of each of these domains (3)
to assess the effect of selective inhibitors on E. histolytica in cell
culture.
Materials and Methods
Cloning and Protein Purification
A P. falciparum Hsp90 ATP-binding domain construct was
amplified from genomic DNA harvested from the intra-
erythrocytic life cycle of P. falciparum strain 3D7 obtained
from the MR4 Malaria Research and Reference Resource Center
(Forward primer: 5′ CGCCGGCGCCATATGAGTTTTCCAAG
3′ Reverse primer 5′ CGCCGGCGCGGATCCTAAATTCAT
TAAACT 3′) and was cloned into the pET28b vector (Novagen).
The E. histolyticaHsp90 ATP-binding domain was also amplified
from genomic DNA extracted from a frozen E. histolytica (strain
HM1:IMSS) culture obtained from the American Type Culture
Collection (ATCC) (Forward primer: 5′CCGGGATCCATGGGA
AATAGAAAA3 ′) (Reverse primer: 5′GCGCGGTTCGAAATA
TTGAATAAATTC 3′) and was cloned into the pET28a vector
(Novagen).
The clones were expressed in E. coli Bl21 (DE3) Codon
Plus cells (Agilent Technologies) grown in terrific broth (12 g
tryptone, 24 g yeast extract, 17mM KH2PO4, 72mM K2HPO4
and 4mL glycerol per liter broth), and induced with 0.4mM
Isopropyl β-D-1-thiogalactopyranoside (IPTG) overnight at
24◦C. These E. coli cells were harvested by centrifugation
(5000 rpm for 10min), resuspended in lysis buffer (20mM
4- (2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES),
pH 7.5, 10% glycerol, 20mM imidazole, 500mM NaCl,
0.5% nonyl phenoxypolyethoxylethanol NP-40 surfactant) and
supplemented with 100× bacterial protease inhibitor cocktail
(Sigma). Cells were lysed by 5 times 45 s rounds (separated by
a pause of 45 s) of sonication. The cell debris was removed
by centrifugation (14,000 rpm for 30min), and the protein
was purified using nickel-nitrilotriacetic acid (Ni-NTA) resin
(QIAGEN). Tobacco etch virus (TEV) protease was added at a
ratio of 1:50 TEV protease in dialysis buffer [20mM HEPES, pH
7.5, 100mM NaCl, 5mM MgCl2, and 0.01mM 4,40-dianalino-
1,10-binaphthyl-5,50-disulfonic acid dipotassium salt (bis-ANS)]
and incubated overnight at 4◦C. This mixture was washed over
a Ni-NTA column to remove the TEV protease and cleaved
polyhistidine tags from the purified protein. The proteins were
concentrated to ∼10mg/mL using Amicon R© Ultra centrifugal
filters for protein concentration (Millipore) and centrifugation
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at 2800 rpm. The same conditions were used for the expression
and purification of all the proteins used in this study. The
HsHsp90 ATP binding domain pET15b (Novagen) clone was
kindly provided by Dr. Daniel Gewirth (Hauptman-Woodward
Medical Research Institute).
Site-Directed Mutagenesis
Site-directed mutants were generated using site-specific primers
(Supplementary File 2) that target unique residues in the ATP
binding pockets of HsHsp90, PfHsp90, and EhHsp90 proteins.
The site directed mutagenesis procedure was followed as per
instructions of the QuickChange site-directed mutagenesis
kit (Agilent Technologies, Santa Clara, CA) with some
modifications. Briefly, the mutant plasmid was amplified
using the proofreading enzyme Pfx (Invitrogen, Carlsbad, CA).
Denaturation of the initial template was allowed to take place
for 3min at 95◦C. After the initial denaturation, 14 cycles of
denaturation (95◦C), annealing (58◦C) and elongation (68◦C)
took place. The nascent template was digested by the Dpn1
enzyme (37◦C for 1 h), which digests methylated DNA that has
been replicated inside E. coli Dh5-alpha bacteria (Invitrogen),
which were used for the plasmid purification in this case.
The undigested (amplified) plasmids were transformed in
ultracompetent E. coli XL-Gold 10 cells (Agilent Technologies,
Santa Clara, CA). The plasmids were purified using the Qiagen
Miniprep kit (Qiagen, Germantown, MD). These plasmids
were screened for the presence of the mutation using Sanger
sequencing (Applied Biosystems 3130xl, Carlsbad, CA) after
amplification of the Hsp90 ATP binding domain gene using
standard T7 primers and annealing conditions (Novagen,
Madison, WI).
4,40-dianalino-1,10-binaphthyl-5,50-disulfonic
acid dipotassium salt (bis-ANS) Binding Assay
with the PfHsp90 ATP-Binding Domain
By optimization of a previously established technique
(Wassenberg et al., 2000), the fluorescent probe 4,40-dianalino-
1,10-binaphthyl-5,50-disulfonicacid dipotassium salt (bis-ANS,
Sigma-Aldrich) was used to demonstrate nucleotide binding to
the ATP-binding domain of PfHsp90 (Shahinas et al., 2010).
Recombinant purified protein (final protein concentration
1µM) was pre-incubated for 45min at 37◦C with no drug or
in the presence of 200 nL of drug to a final concentration of
100 nM (Spectrum and Lopac libraries) and 50 nM (Prestwick
library). bis-ANS was then added to a final concentration
of 5µM in binding buffer [20mM tris(hydroxymethyl)
aminomethane(Tris) pH 7.5, 10mM MgCl2, 50mM KCl] in
a final volume of 20µL and incubated at 37◦C for 30min.
In order to facilitate the high throughput screening of 4000
compounds, all these volumes were optimized for robotic
handling. Drug distribution was carried out using a pintool that
can accurately dispense 200 nL volumes. Fluorescence emission
data were collected on an EnVision fluorescent monochromator
spectrophotometer (Perkin-Elmer Life Sciences). Excitation
wavelength for bis-ANS was set at 372 nm, and emission was
captured at 490 nm. All chemical compounds had 99% purity by
high performance liquid chromatography (HPLC).
Entamoeba histolytica Culture Experiments
E. histolytica trophozoites (HM1:IMSS strain from ATCC) were
maintained in TYI-S-33 medium (20 g casein digest, 10 g yeast
extract, 10 g glucose, 2 g sodium chloride, 1 g L-cysteine HCl,
0.2 g ascorbic acid, 1 g K2HPO4, 0.6 g KH2PO4, 28.75mg
ferric nitrate per liter) that was supplemented with penicillin
(100U/mL), streptomycin (100µg/mL), and 10% adult bovine
serum, under axenic conditions according to the methods of
Diamond (Diamond et al., 1978; Debnath et al., 2004, 2005).
All of the experiments were conducted with trophozoites that
had been harvested during the logarithmic phase of growth.
The logarithmic phase of growth was determined by counting
the cells using the particle counter (Beckman Coulter) and the
cells were maintained in this growth phase by routine passage
every 2 days. Compounds were tested for antiparasitic activity
using an ATP-bioluminescence based screen for cell growth and
survival (Debnath et al., 2012). Assay plates were inoculated
with trophozoites (5 × 103 parasites/well) and incubated in
the GasPak™ EZ Anaerobe Gas Generating Pouch Systems
(VWR, West Chester, PA) to maintain anaerobic conditions
throughout the incubation period. The assays were performed
in triplicate using the CellTiter-Glo Luminescent Cell Viability
Assay (Promega). Metronidazole was used as a positive control
because it is the current treatment for E. histolytica infection.
Results
Homology Modeling Reveals Ortholog-specific
Residues in the N-terminal ATP-binding Domain
of Hsp90
Homology modeling studies using the crystal structures of
PfHsp90 (PDB accession no. 3K60) and HsHsp90 (PDB accession
no. 2FWZ) and the homology model of EhHsp90 ATP-binding
domain suggest that although the pocket is overall very well
conserved, there are three corresponding positions that contain
unique residues in the three structures (Figure 1). Ser52, Asn106,
and Lys112 in HsHsp90 correspond to Ala38, Asn92, and
Arg98 in PfHsp90 and Cys49, Cys103 and Arg109 in EhHsp90.
This finding suggests that the ATP-binding pocket of EhHsp90
may not be as constricted as that of PfHsp90 but it is more
hydrophobic than that of PfHsp90 and HsHsp90.
Biochemical Screen with Recombinant EhHsp90
ATP-binding Domain
We have previously reported the results of an initial screen
vs. HsHsp90 and PfHsp90 based on competitive inhibition of
bis-ANS binding with 4000 compounds consisting of natural
compounds [Spectrum], FDA approved drugs [Prestwick], and
pharmacologically active compounds [Lopac] (Shahinas et al.,
2010). Forty-three compounds were identified that caused a
reduction of>70% in fluorescence against HsHsp90 and PfHsp90
ATP binding domains, suggesting competitive inhibition of
ATP-binding (Shahinas et al., 2010). This threshold of >70%
fluorescence inhibition was set based on Hsp90 inhibition by
radicicol, a well-known cross-species Hsp90 inhibitor (Schulte
et al., 1998, 1999). Screening of these 43 inhibitors against
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the EhHsp90 ATP-binding domain showed that 19 of them
competitively inhibit this domain by >70% (Figure 2).
Site-directed Mutagenesis of Unique Residues in
Orthologous Hsp90 ATP-binding Domains Affects
Inhibitor Selectivity
To determine the importance of the three unique positions
tabulated in Figure 1D, site directed mutants were generated
at each of those sites in the corresponding vectors. The
proteins were expressed and the affinity of each mutant for any
of the 43 compounds was determined based on competitive
inhibition of bis-ANS binding using the same conditions
as for the wild-type proteins. Even though, the expression
level and yield varied among the different mutants, equal
concentration of each protein was used to test competitive
inhibition with bis-ANS. The top 10 inhibitors for the
FIGURE 1 | Illustration of ATP binding pocket differences. (A)
Molecular model of adenosine diphosphate (ADP) in the adenosine
triphosphate (ATP) binding pocket of human (2FWZ) Hsp90 (HsHsp90). (B)
Molecular model of ADP in the ATP binding pocket of P. falciparum (3K60)
Hsp90 (PfHsp90). (C) Molecular model of ADP in the ATP binding pocket of
E. histolytica Hsp90 (EhHsp90) (based on PfHsp90 template: 3K60). (D)
Summary of the unique residues in the ATP binding pockets of HsHsp90,
PfHsp90 and EhHsp90. Please note that these residues are at conserved
positions in the 3D model. These residues were mutated by site-directed
mutagenesis to examine alterations in binding specificity.
FIGURE 2 | Competitive binding assay using the fluorescent probe
bis-ANS for the identification of EhHsp90 inhibitors at a final
concentration of 2.5 µM. The error bars represent standard deviation of
duplicate readings. Inhibition is defined as >70% reduction of fluorescence in
this assay. Compounds 1–43 are listed in Supplementary File 1. Please
note that 48 compounds are shown, of which five could not be obtained any
longer from the manufacturer. Therefore, the manuscript focuses on the rest
43 compounds, which were used for downstream assays.
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FIGURE 3 | Drug binding specificity of the Hsp90 ATP binding
domains and their mutants. Top 10 inhibitors are shown for each of the
wild-type (WT) or site-directed mutant ATP binding domains. Any inhibitors in
overlapping ovals are not selective. Inhibition was evaluated by competition
for bis-ANS binding. Top 10 inhibitors of the HsHsp90 (A), PfHsp90 (B),
EhHsp90 (C) ATP binding domains and the mutants generated in each
domain, respectively. (D) Top 10 inhibitors of HsHsp90 and mutants that
mimic HsHsp90 residues at the corresponding positions (1). (E) Top 10
inhibitors of HsHsp90 and mutants that mimic HsHsp90 residues at the
corresponding positions (2). (F) Top 10 inhibitors of PfHsp90 and mutants
that mimic PfHsp90 residues at the corresponding positions. (G) Top 10
inhibitors of EhHsp90 and mutants that mimic EhHsp90 residues at the
corresponding positions. The abbreviations for the drugs displayed in this
figure are listed in Supplementary File 1.
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wild-type (WT) protein and each mutant are shown relative
to each other in the Venn diagrams of Figure 3. Venn
diagrams show common inhibitors that compete for binding
TABLE 1 | Summary of inhibition results for the EhHsp90 protein screen
and the effect of the inhibitors on E. histolytica culture.
Compound Percent inhibition of Percent inhibition of
fluorescence in protein E. histolytica growth
screen at 2.5µM (%) at 25µM (%)
GW5074 70.5 –
Sanguinarine sulfate 71.3 –
Rifabutin 73.7 30
Bilirubin 73.7 –
Clofazimine 73.7 –
Purpurin 75.0 –
Tyrphostin AG 538 75.0 –
Rutilantin 77.1 100
Rifaximin 78.2 –
Berberine chloride 78.3 –
Chlorophyllide 78.9 –
Amodiaquindihydrochloride
dihydrate
82.1 –
Daunorubicin
hydrochloride
83.2 –
WB 64 (Malachite Green) 84.9 –
Hycanthone 90.9 –
Mitoxantronedihydrochloride 95.3 –
Cetylpyridinium chloride 95.9 42
Pararosanilinepamoate 99.0 81
Gentian Violet 99.3 35
(overlapping ellipses) and unique inhibitors that compete for
binding of this ATP binding domain (where no overlap is
observed). It is important to note that most of these residues
confer selectivity of binding for the 43 inhibitors tested.
There are three inhibitors among the 43 tested that show
consistent non-selective high inhibition: quinacrine (QNC),
curcumin (CUR), and ethaverine hydrochloride (ETH). The
abbreviations used for the drugs shown in Figure 3 are listed in
Supplementary File 1.
EhHsp90 Inhibitor Effect on Cell Culture
The hits of the protein screen were next tested against a
standard lab strain of E. histolytica HM1:IMSS in vitro. Five out
of the 19 EhHsp90 protein hits inhibited E.histolytica growth
(replication of trophozoites) in the range of 30–100% at the
concentration of 25µM (Table 1). These five compounds were:
rifabutin, rutilantin, cetylpyridinium chloride, pararosaniline
pamoate, and gentian violet. Based on the site directed
mutagenesis experiment outlined above, rifabutin showed the
highest inhibition against PfHsp90 and displayed amino acid
preferences for A38, N92, and R98. Rutilantin was present in
the top 10 inhibitors of the HsHsp90 and PfHsp90 constructs
and displayed preference for N106 in HsHsp90 and N92 in
the corresponding position of PfHsp90. Pararosaniline pamoate
and gentian violet showed highest inhibition for the EhHsp90
construct and displayed preference of binding as assessed by
competitive inhibition for C49, C103, and R109. These results
are summarized in Table 2. From these five compounds, it was
possible to obtain titration curves for pararosaniline pamoate
and rutilantin with IC50s of 1.1µM and 2µM, respectively
(Figure 4).
TABLE 2 | Summary of biochemical specificity results for inhibitors of E.histolytica in culture.
Drug Chemical structure Highest % inhibtion Amino acid prefernce
Rifabutin (RIF) PfHsp90 PfHsp90: A38 + N92 + R98
Rutilantin (RUT) HsHsp90 & PfHsp90 HsHsp90: N106 PfHsp90: N92
Cetylpyridinium chloride (CPC) EhHsp90 EhHsp90: C49 + C103 + R109
Pararosaniline pamoate (PSP) EhHsp90 EhHsp90: C49 + C103 + R109
Gentian Violet (GVI) EhHsp90 EhHsp90: C49 + C103 + R109 HsHsp90: S52A or Kll2R
The chemical structures shown here have been adapted from ChemDB (Pavithra et al., 2007; Corbett and Berger, 2010).
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FIGURE 4 | Anti-amebic activity of (A) pararosaniline pamoate (IC50 =
1.1µM) and (B) rutilantin (IC50 = 2.0µM) using a standard cell-based
assay. Mean IC50 curves are shown. Error bars represent standard deviation
of triplicate samples.
Discussion
The discovery of five compounds that target HSP90 and
inhibit E. histolytica growth has significant implications for
antiparasitic drug development. Amebiasis caused by E. hisolytica
is responsible for 35–50 million cases of symptomatic disease and
about 100,000 deaths per year (Ralston and Petri, 2011b). Parasite
cysts are transmitted through contaminated food and water
(Stanley, 2003). Currently, nitroimidazoles (metronidazole) are
prescribed for treatment, but despite toxic side effects, cure is not
reached in 40–60% of the patients (Ralston and Petri, 2011b).
In addition, novel drugs for E. histolytica are urgently needed
as the approved therapy (metronidazole) may result in clinical
treatment failure due to resistance.
Infection occurs after ingestion of cysts and may lead to
liver abscess (Ralston and Petri, 2011a,b). Parasite excystation in
the small intestine produces eight trophozoites per cyst, which
colonize the large intestine, existing both in the lumen and
attached to mucus and epithelial cells (Petri et al., 2002). Not all
strains have the same virulence and are capable of causing liver
abscess (Ralston and Petri, 2011b). Chaperoning of virulence
factors by stress-inducible Hsp90 is likely to be important.
Therefore, inhibition of Hsp90 ATP binding is a compelling
strategy for antiparasitic drug design.
Our recombinant Hsp90 ATP-binding domain assay relies
on competitive inhibition of bis-ANS competes with ATP
for the ATPase domain and emits fluorescence upon binding
at the hydrophobic pocket (Wassenberg et al., 2000). This
suggests that the hit compounds identified here compete for
the ATP-binding domain. While the full binding mode has not
been fully elucidated for these hits, the Hsp90 ATP-binding
domain contains several basic and hydrophobic residues that are
characteristic of protein binding pockets that bind structurally
diverse compounds (Dutta and Inouye, 2000).
Only 19 out of the 43 compounds inhibited bis-ANS binding
of the EhHsp90 ATP binding domain and 43 of the 43
compounds inhibited the HsHsp90 ATP binding domain. This
result suggests that there is sufficient biochemical diversity in
this pocket to allow for ortholog selectivity of some of these
compounds. This hypothesis was further tested by the site
directed mutagenesis study which showed selective binding of
most of the 43 drugs tested upon switch of one of the three
unique residues in each of the binding pockets of EhHsp90,
PfHsp90, and HsHsp90. This experiment showed that sufficient
structural diversity in the ATP-binding pocket of Hsp90 allows
for ortholog selectivity of Hsp90 through manipulation of
the architecture of EhHsp90, malaria and human Hsp90 by
mutagenesis.
The 19 EhHsp90 hits were further tested against live E.
histolytica trophozoites. Five of the 19 compounds exhibited
inhibitory activity in vitro. The other 14 compounds may
not have been able to penetrate the plasma membrane of
the trophozoites in vitro or otherwise access EhHsp90. The
five inhibitors of EhHsp90 with promising activity against the
parasite were rifabutin, rutilantin, cetylpyridinium chloride,
pararosaniline pamoate, and gentian violet. Rifabutin is a
rifamycin-class antibiotic with an ansamycin moiety (O’Brien
et al., 1987, 1990). Ansamycin inhibitors such as geldanamycin
are well characterized inhibitors of the chaperone activity
of Hsp90 (Bohen, 1998; Onuoha et al., 2007; Porter et al.,
2009). Both rifamycin and rifabutin have been used widely
against mycobacteria (O’Brien et al., 1987, 1990), but there is
no report of their use against amebiasis. Other studies have
suggested that rifabutin is effective against cryptosporidiosis,
another intestinal parasitic infectious disease (Holmberg et al.,
1998; Fichtenbaum et al., 2000). The antibiotic rutilantin
has antiphage and antiviral activity (Asheshov and Gordon,
1961; Hume et al., 1965). Cetylpyridinium chloride is an
antiseptic compound that is used in mouthwash and other
mouth/throat care products (Sheen et al., 2003; Herrera
et al., 2005; Gunsolley, 2008; Herrera, 2009; Rioboo et al.,
2011). Potent activity has also been reported against a fungal
pathogen: Candida albicans (Jones et al., 1995). Pararosaniline
pamoate has already been used as an antiparasitic drug against
schistosomiasis in the Philippines (Pesigan et al., 1967). This
compound has shown anti-Hsp90 activity in another high
throughput screen as well (United States Patent Application
20110263693). Gentian violet is also known as crystal violet
and is one of the constituents of the Gram stain used to
visualize bacteria (Berberovic, 1953; Saji et al., 1994). 1%
solution of gentian violet is reported as a treatment for C.
albicans infections (Traboulsi et al., 2011). Gentian violet
and pararosaniline pamoate are structurally related molecules
(triarylmethanes group). Considering this previous literature and
actual usage, these drugs come with known pharmacokinetic,
pharmacodynamics, and safety profiles that allow bypassing
of the initial evaluation of bioavailability, metabolic stability,
adsorption, and excretion.
Conclusion
ATP is required for client protein and co-chaperone binding
with Hsp90 (Prodromou et al., 1997). Therefore, inhibition of the
Hsp90 ATP binding is lethal in all higher organisms studied to
date and may prove effective in the treatment of amebiasis. The
efficacy and safety of these candidate drugs needs to be reassessed
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in animal models. Even if the repurposed drug candidates
reported here do not turn out to be optimal antiamebic agents,
they provide a starting point for further structure-based drug
design. Novel drugs for amebiasis as well as other neglected
tropical diseases are urgently needed and Hsp90 provides a
radically new target whereby resistance can be circumvented. The
long term goal of these preliminary studies is co-formulation of
drug combinations including Hsp90 inhibitors.
Supplementary Material
The Supplementary Material for this article can be found
online at: http://journal.frontiersin.org/article/10.3389/fmicb.
2015.00368/abstract
Supplimentary File 1 | The list of chemical name abbreviations used
throughout the manuscript.
Supplimentary File 2 | List of primers used for site-directed mutagenesis.
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